Inflammatory breast carcinoma and noninflammatory locally advanced breast carcinoma: distinct clinicopathologic entities?

PURPOSE Inflammatory breast carcinoma (IBC) and noninflammatory locally advanced breast carcinoma (LABC) are both associated with poor prognosis; however, whether they are distinct clinicopathologic entities remains controversial. MATERIALS AND METHODS To determine whether IBC and LABC were different, we compared tumor characteristics, prognosis, and age-specific incidence rate patterns in the Surveillance, Epidemiology, and End-Results program. An age of 50 years served as a surrogate marker for menopause. RESULTS Younger age at diagnosis, poorer tumor grade, and negative estrogen receptors (ERs) were more predictive of IBC (n = 2,237) than of LABC (n = 7,985). Breast carcinoma survival was worse for patients with IBC than for those with LABC (log-rank test, P <.0001). Age-specific incidence rates for IBC increased until 50 years and then flattened, whereas rates for LABC increased for all ages. When rates for LABC were stratified by estrogen receptor-positive (ERP) and -negative (ERN) expression, rates for ERP and ERN diverged; that is, rates for ERP increased with advancing age, whereas rates for ERN flattened after 50 years. When rates for IBC were stratified by ER expression, rates for both ERP and ERN flattened after 50 years of age. CONCLUSION IBC and LABC seemed to be distinct biologic entities, as indicated by different prognostic factor profiles and age-specific incidence rate patterns. Rates that increased before 50 years and then stabilized, possibly indicated that premenopausal exposures had a greater effect on maintaining rates for IBC than for LABC.

[1]  Nilanjan Chatterjee,et al.  Estrogen Receptor Breast Cancer Phenotypes in the Surveillance, Epidemiology, and End Results Database , 2002, Breast Cancer Research and Treatment.

[2]  R. Tarone,et al.  The greater impact of menopause on ER– than ER+ breast cancer incidence: a possible explanation (United States) , 2002, Cancer Causes & Control.

[3]  J. Potter,et al.  The shape of age–incidence curves of female breast cancer by hormone-receptor status , 1999, Cancer Causes & Control.

[4]  I. Henderson,et al.  The relationship between prognostic and predictive factors in the management of breast cancer , 2004, Breast Cancer Research and Treatment.

[5]  Ahmedin Jemal,et al.  Annual Report to the Nation on the status of cancer, 1973–1999, featuring implications of age and aging on U.S. cancer burden , 2002, Cancer.

[6]  S. Narod Modifiers of risk of hereditary breast and ovarian cancer , 2002, Nature Reviews Cancer.

[7]  J. Peto,et al.  Genetics and the common cancers. , 2001, European journal of cancer.

[8]  J. Peto,et al.  High constant incidence in twins and other relatives of women with breast cancer , 2000, Nature Genetics.

[9]  R. Elledge,et al.  Tumor characteristics and clinical outcome of elderly women with breast cancer. , 2000, Journal of the National Cancer Institute.

[10]  A. Buzdar,et al.  Inflammatory breast carcinoma incidence and survival , 1998, Cancer.

[11]  D. Wilke,et al.  Inflammatory breast carcinoma: comparison of survival of those diagnosed clinically, pathologically, or with both features. , 1998, The American surgeon.

[12]  P. Hartge,et al.  The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. , 1997, The New England journal of medicine.

[13]  M. Seller,et al.  Unusual case of Smith-Lemli-Opitz syndrome "type II". , 1995, American journal of medical genetics.

[14]  D. Allred,et al.  Breast cancer outcome and predictors of outcome: are there age differentials? , 1994, Journal of the National Cancer Institute. Monographs.

[15]  M. Pike,et al.  Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. , 1993, Epidemiologic reviews.

[16]  G. Clark The biology of breast cancer in older women. , 1992, Journal of gerontology.

[17]  A Morabia,et al.  Misclassification bias related to definition of menopausal status in case-control studies of breast cancer. , 1992, International journal of epidemiology.

[18]  S. Romain,et al.  Inflammatory carcinoma of the breast. , 1992, European journal of gynaecological oncology.

[19]  W. Donegan,et al.  Combined therapy for inflammatory breast cancer. , 1990, Archives of surgery.

[20]  L. R. Hill,et al.  Inflammatory breast carcinoma: A distinct entity? , 1985, Journal of surgical oncology.

[21]  P. Levine,et al.  Inflammatory breast cancer: the experience of the surveillance, epidemiology, and end results (SEER) program. , 1985, Journal of the National Cancer Institute.

[22]  A. Cooperman,et al.  Inflammatory breast cancer. , 1985, The Surgical clinics of North America.

[23]  C. Perez-Mesa,et al.  Inflammatory carcinoma of the breast , 1978, Cancer.

[24]  S. Saltzstein,et al.  Clinically occult inflammatory carcinoma of the breast , 1974, Cancer.

[25]  P. Rosen,et al.  Inflammatory carcinoma of the breast. , 1938, The Surgical clinics of North America.

[26]  J. Peto,et al.  Asymptotically Efficient Rank Invariant Test Procedures , 1972 .

[27]  D. Cox Regression Models and Life-Tables , 1972 .